The Journal of endocrinology, 138(1), 31-40 (1993-07-01)
We have reported that 19-hydroxyandrostenedione (19-OH-A-dione) amplifies the sodium-retaining action of aldosterone. To evaluate whether it also amplifies the hypertensive action of small doses of aldosterone, mononephrectomized rats were given 0.5 mg aldosterone, 10 mg 19-OH-A-dione or a combination of
Aromatase activity in the foetal rat testis was demonstrated by the conversion of [3H] testosterone into oestradiol. However, the conversion rate was low, around 0.06%, probably because the radioactive precursor was heavily diluted by the large amounts of endogenous testosterone
[Hypertensinogenic steroid].
M Soma et al.
Nihon rinsho. Japanese journal of clinical medicine, 47(9), 2104-2108 (1989-09-01)
Journal of steroid biochemistry, 35(3-4), 507-510 (1990-03-01)
Ovaries from 18-21-day-old foetal as well as from 2-10-day-old infantile rats were cultured in vitro in the presence of [3H]19-hydroxyandrostenedione and in the presence or absence of LH, FSH or (Bu)2 cAMP, and oestrone and oestradiol formed were determined by
In order to evaluate the hypertensinogenic action of 19-hydroxyandrostenedione (19-OH-AD), which has been reported to be an amplifier of mineralocorticoid, the changes in several humoral factors were observed in 19-OH-AD treated rats as compared to those in DOCA hypertensive rats.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.